Pfizer Pharmaceutical Company Faces Share Decline as Twice-Daily Obesity Treatment Abandoned Due to High Dropout Rates in Clinical Trial
In a significant development, Pfizer Pharmaceutical Company faced a downturn in its shares on Friday as it announced the discontinuation of a twice-daily obesity treatment due to a high dropout rate among patients in a clinical trial. Pfizer Pharmaceutical Company, acknowledging the challenges, revealed that it would pivot its focus towards a once-daily variant of … Read more